<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01844791</url>
  </required_header>
  <id_info>
    <org_study_id>OCZ103-206</org_study_id>
    <nct_id>NCT01844791</nct_id>
  </id_info>
  <brief_title>An Exploratory Study of OCZ103-OS in Combination With Standard of Care in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients</brief_title>
  <official_title>A Phase IIa Exploratory Study of OCZ103-OS in Combination With Platinum-Gemcitabine Based Doublet First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC) Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncozyme Pharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oncozyme Pharma Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the safety and efficacy of the use of OCZ103-OS&#xD;
      in combination with Platinum-Gemcitabine based doublet first line therapy in stage IV&#xD;
      non-small cell lung cancer (NSCLC) patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a single arm, open label study to investigate the safety and efficacy of the use of&#xD;
      OCZ103-OS in combination with Platinum-gemcitabine base doublet first line therapy in stage&#xD;
      IV non-small cell lung cancer (NSCLC) patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">January 2014</completion_date>
  <primary_completion_date type="Actual">January 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Response</measure>
    <time_frame>one year four months</time_frame>
    <description>To assess the effect of OCZ103-OS on overall objective response in subjects with stage IV non-small cell lung cancer.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>OCZ103-OS, Platinum, Gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>OCZ103-OS in combination with Platinum-Gemcitabine as standard of care</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OCZ103-OS</intervention_name>
    <description>OCZ103-OS is given in combination with chemotherapy each cycle</description>
    <arm_group_label>OCZ103-OS, Platinum, Gemcitabine</arm_group_label>
    <other_name>pentamidine bis(2-hydroxyethanesulfonate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Platinum</intervention_name>
    <description>Platinum is given as standard chemotherapy each cycle</description>
    <arm_group_label>OCZ103-OS, Platinum, Gemcitabine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Gemcitabine is given as standard chemotherapy each cycle</description>
    <arm_group_label>OCZ103-OS, Platinum, Gemcitabine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written Informed Consent;&#xD;
&#xD;
          -  Males or females;&#xD;
&#xD;
          -  18-75 years;&#xD;
&#xD;
          -  Histologically or cytologically confirmed stage IV NSCLC patients that are eligible to&#xD;
             platinum-gemcitabine based doublet therapy (M1a and M1b, seventh edition descriptor of&#xD;
             the Revised International System for Staging Lung Cancer, adopted by the AJCC.)&#xD;
             Patients with a prior diagnosis of stage IIIa or IIIb NSCLC who have progressed to&#xD;
             stage IV are also eligible;&#xD;
&#xD;
          -  ECOG performance 0 or 1;&#xD;
&#xD;
          -  One or more tumor lesions measurable by RECIST criteria version 1.1, on CT scan or&#xD;
             MRI;&#xD;
&#xD;
          -  Patients with previous radiotherapy as definitive therapy for locally advanced&#xD;
             non-small cell lung cancer are eligible, as long as the selected measurable lesions&#xD;
             are outside the original radiation therapy port unless there has been demonstrated&#xD;
             progression in the lesion. Radiation therapy must have been completed &gt; 4 weeks prior&#xD;
             to study entry;&#xD;
&#xD;
          -  Palliative radiotherapy must have been completed &gt; 2 weeks prior to study entry.&#xD;
             Concomitant palliative radiotherapy to an existing bone lesion for pain control is&#xD;
             allowed;&#xD;
&#xD;
          -  Life expectancy of at least 3 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any prior systemic therapy for recurrent or metastatic NSCLC, except prior neoadjuvant&#xD;
             or adjuvant systemic chemotherapy for NSCLC if administered at least 6 months prior to&#xD;
             enrolment;&#xD;
&#xD;
          -  Any of the following conditions: Ongoing cardiac dysrhythmias of NCI CTCAE grade â‰¥ 2;&#xD;
             atrial fibrillation of any grade; QTc interval &gt; 450 msec for males or &gt; 470 msec for&#xD;
             females or uncontrolled intercurrent illness, e.g. unstable angina; severe coronary&#xD;
             disease, ventricular arrhythmias, bradycardia &lt; 50 bpm; a history of additional risk&#xD;
             factors for torsades de pointes (e.g., heart failure, hypokalemia or family history of&#xD;
             Long QT Syndrome);&#xD;
&#xD;
          -  Systolic Blood Pressure &lt; 100 mmHg (if deemed clinically significant by the treating&#xD;
             physician);&#xD;
&#xD;
          -  Uncontrolled diabetes. Patients with well controlled diabetes, with a HbA1C of less&#xD;
             than 7%, on stable hypoglycaemic therapy and diet, are eligible;&#xD;
&#xD;
          -  Clinically significant renal impairment or chronic pancreatitis;&#xD;
&#xD;
          -  History of clinically significant hypoglycemia, with fasting blood glucose &lt; 3 mmol/L;&#xD;
&#xD;
          -  Inadequate baseline organ function as shown by following laboratory values:&#xD;
&#xD;
          -  Hemoglobin &lt; 100 g/L&#xD;
&#xD;
          -  Absolute neutrophil count &lt;1.5 x 10e9/L&#xD;
&#xD;
          -  Platelet count &lt; 100 x 10e9/L&#xD;
&#xD;
          -  Total bilirubin &gt; 1.5 x ULN&#xD;
&#xD;
          -  AST and ALT &gt; 2.5 x ULN or &gt; 5 ULN in the presence of liver metastases&#xD;
&#xD;
          -  Serum creatinine &gt; 1.5 x ULN or calculated creatinine clearance &lt; 60 ml/min&#xD;
&#xD;
          -  To be dependent of oxygen treatment;&#xD;
&#xD;
          -  Active infections requiring antibiotics;&#xD;
&#xD;
          -  A major surgical procedure, open biopsy, or significant traumatic injury within 28&#xD;
             days of beginning treatment, or anticipation of the need for major surgery during the&#xD;
             course of the study;&#xD;
&#xD;
          -  Pregnancy or breastfeeding. All women of child-bearing potential must have a negative&#xD;
             pregnancy test prior to first receiving protocol therapy;&#xD;
&#xD;
          -  Active alcohol or drug abuse;&#xD;
&#xD;
          -  Known or suspected allergy/hypersensitivity to any agent given in the course of this&#xD;
             trial;&#xD;
&#xD;
          -  Any co-morbid condition that in the judgment of the investigator renders the subject&#xD;
             at high risk of treatment complication or reduces the probability of assessing&#xD;
             clinical effect;&#xD;
&#xD;
          -  Other malignancies diagnosed within the last 5 years with the exception of Basal Cell&#xD;
             Carcinoma of the skin;&#xD;
&#xD;
          -  Patients unable to comply with the study protocol and follow-up schedule for any&#xD;
             psychological, familial, sociological or geographical reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ewa Kalinka-Warzocha, MD-PhD</last_name>
    <role>Study Director</role>
    <affiliation>Wojewodzki Szpital Specjalistyczny im .M. Kopernika w</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ewa Kalinka-Warzocha</name>
      <address>
        <city>Lodz</city>
        <zip>93-513</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Poland</country>
  </location_countries>
  <verification_date>October 2014</verification_date>
  <study_first_submitted>April 29, 2013</study_first_submitted>
  <study_first_submitted_qc>April 29, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 1, 2013</study_first_posted>
  <last_update_submitted>October 20, 2014</last_update_submitted>
  <last_update_submitted_qc>October 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non-small cell lung cancer</keyword>
  <keyword>OCZ103-OS</keyword>
  <keyword>Pentamidine bis(2-hydroxyethanesulfonate)</keyword>
  <keyword>platinum-gemcitabine based doublet first line therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Pentamidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

